A randomized, double-blind, placebo-controlled study to determine tolerability and safety of different dosages of SUBLIVAC FIX Mite mixture in patients with allergic rhinitis / rhinoconjunctivitis caused by house dust mites.

Trial Profile

A randomized, double-blind, placebo-controlled study to determine tolerability and safety of different dosages of SUBLIVAC FIX Mite mixture in patients with allergic rhinitis / rhinoconjunctivitis caused by house dust mites.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs House dust mite allergy immunotherapy sublingual HAL Allergy (Primary)
  • Indications Allergic rhinitis; Allergic rhinoconjunctivitis
  • Focus Adverse reactions
  • Acronyms DTS
  • Sponsors HAL Allergy
  • Most Recent Events

    • 01 Dec 2015 Status changed from recruiting to completed as per ClinicalTrials.gov.
    • 11 May 2015 Planned End Date changed from 1 Jul 2015 to 1 Oct 2015 as per ClinicalTrials.gov record.
    • 11 May 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Oct 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top